Table 3 Prevalence of most common (≥10% of patients) TEAEs (any grade) for ibrutinib+BR-randomized patients

From: Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

n (%)

0–1 year (n = 287)

1–2 years (n = 219)

2–3 years (n = 188)

3–4 years (n = 79)

Overall (N = 287)

Patients with any TEAE

278 (96.9)

185 (84.5)

156 (83.0)

62 (78.5)

282 (98.3)

TEAEs reported in ≥10% of patients

 Neutropenia

164 (57.1)

43 (19.6)

9 (4.8)

0

167 (58.2)

 Diarrhea

98 (34.1)

39 (17.8)

21 (11.2)

7 (8.9)

110 (38.3)

 Nausea

105 (36.6)

9 (4.1)

7 (3.7)

1 (1.3)

106 (36.9)

 Thrombocytopenia

86 (30.0)

10 (4.6)

7 (3.7)

3 (3.8)

89 (31.0)

 Anemia

64 (22.3)

5 (2.3)

5 (2.7)

1 (1.3)

68 (23.7)

 Pyrexia

69 (24.0)

11 (5.0)

6 (3.2)

0

78 (27.2)

 Cough

48 (16.7)

25 (11.4)

21 (11.2)

4 (5.1)

65 (22.6)

 Fatigue

58 (20.2)

18 (8.2)

16 (8.5)

8 (10.1)

67 (23.3)

 Pneumonia

38 (13.2)

20 (9.1)

16 (8.5)

1 (1.3)

61 (21.3)

 Upper respiratory tract infection

38 (13.2)

24 (11.0)

10 (5.3)

2 (2.5)

61 (21.3)

 Bronchitis

33 (11.5)

15 (6.8)

11 (5.9)

2 (2.5)

50 (17.4)

 Sinusitis

22 (7.7)

14 (6.4)

11 (5.9)

0

33 (11.5)

 Nasopharyngitis

21 (7.3)

13 (5.9)

4 (2.1)

1 (1.3)

30 (10.5)

 Constipation

53 (18.5)

13 (5.9)

14 (7.4)

5 (6.3)

57 (19.9)

 Rash

45 (15.7)

23 (10.5)

9 (4.8)

4 (5.1)

56 (19.5)

 Infusion-related reaction

48 (16.7)

0

0

0

48 (16.7)

 Headache

41 (14.3)

11 (5.0)

8 (4.3)

6 (7.6)

45 (15.7)

 Vomiting

40 (13.9)

3 (1.4)

2 (1.1)

0

42 (14.6)

 Edema peripheral

32 (11.1)

16 (7.3)

13 (6.9)

7 (8.9)

42 (14.6)

 Muscle spasms

34 (11.8)

17 (7.8)

20 (10.6)

7 (8.9)

40 (13.9)

 Decreased appetite

35 (12.2)

9 (4.1)

2 (1.1)

0

38 (13.2)

 Abdominal pain

30 (10.5)

8 (3.7)

7 (3.7)

2 (2.5)

37 (12.9)

 Arthralgia

28 (9.8)

19 (8.7)

11 (5.9)

3 (3.8)

37 (12.9)

 Febrile neutropenia

32 (11.1)

2 (0.9)

2 (1.1)

0

36 (12.5)

 Back pain

29 (10.1)

8 (3.7)

10 (5.3)

3 (3.8)

36 (12.5)

 Hypertension

23 (8.0)

20 (9.1)

20 (10.6)

7 (8.9)

35 (12.2)

 Hyperuricemia

27 (9.4)

7 (3.2)

10 (5.3)

3 (3.8)

35 (12.2)

 Chills

31 (10.8)

3 (1.4)

2 (1.1)

0

33 (11.5)

 Pruritus

29 (10.1)

11 (5.0)

7 (3.7)

2 (2.5)

32 (11.1)

  1. BR bendamustine and rituximab, TEAE treatment-emergent adverse event